cell therapy
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
PolTreg T-Regulatory Cell Therapy Shows Clinical Remission in Type 1 Diabetes for up to 12 Years
The company is now seeking partnership funding to launch a pivotal Phase II/III study of the autologous T-regulatory cell therapy.
IN8bio to Lay off Nearly Half of Workforce, Narrow Pipeline Focus on AML Cell Therapy
The firm is dropping two glioblastoma programs and cutting 49 percent of its staff to advance its gamma delta T-cell therapy INB-100 in post-transplant AML.
FDA Clears Medigene's IND for TCR-T Therapy in Certain Advanced Solid Tumors
The firm plans to launch a Phase I trial for the autologous TCR-T cell therapy by year-end if additional funding comes through.